Lafora’s odyssey reaches a mysterious port of call

In 1911, the Spanish neurologist-pathologist Gonzalo Lafora, working at the then Government Hospital for the Insane in Washington DC, first described the progressive myoclonus epilepsy that would later bear his name (Lafora, 1911). The journey to understand this disease started with Lafora’s detailed neuropathological description of the large and profuse inclusions (Fig. 1) that would come to be known as Lafora bodies. The odyssey has visited many a shore, and the latest and most mysterious is revealed by Javier Gayarre et al. (2014) in this issue of Brain. Lafora bodies as drawn by Lafora in his original manuscript (Lafora, 1911). Whereas the ‘amyloid’ plaques of Alzheimer’s disease are not in fact amyloid (starch), Lafora bodies, by contrast, are. Lafora bodies are composed of hyperphosphorylated and malformed glycogen molecules. These abnormal starch-like polyglucosans aggregate to form insoluble masses, which over time accumulate inside neuronal somata and dendrites. Lafora disease is caused by loss-of-function mutations in the EPM2A (laforin) or EPM2B (malin) genes (Minassian et al., 1998; Chan et al., 2003). Laforin is the only known glycogen phosphatase. Its absence leads to hyperphosphorylation of glycogen, which correlates with a gradual accumulation of polyglucosans, strongly suggesting that glycogen hyperphosphorylation underlies polyglucosan formation (Tagliabracci et al., 2008). Laforin’s structure resembles that of the plant starch phosphatase SEX4, which is crucial to starch metabolism; its absence leading to a pathological excess of starch. Laforin complements SEX4 and rescues the starch-excess phenotype of SEX4-deficient plants (Gentry et al., 2007). The phosphatase activity of laforin is its only known enzymatic function. Together, these findings suggest a central role for impaired glycogen dephosphorylation by laforin in Lafora disease pathogenesis. As for the enzyme behind glycogen phosphorylation, despite many efforts to identify it, that shore remains unattained. Malin, meanwhile, has been shown to be a ubiquitin E3 ligase. Paradoxically, malin’s only unequivocal target for proteasomal degradation turns out to be none other than laforin (Gentry et al., 2005). How can the absence of malin lead to the same disease as does absence of the protein, laforin, that malin destroys? A solution to this conundrum was suggested by recent work which revealed that, in the absence of malin, laforin accumulates in glycogen and may thus disturb the spherical architecture that is essential for glycogen’s solubility (Tiberia et al., 2012). As such, excess phosphate in glycogen (as a result of laforin deficiency) or excess laforin in glycogen (due to malin deficiency) would have the same effect on glycogen, reducing its solubility and leading it to precipitate and form Lafora bodies. In the current issue of Brain, Gayarre et al. (2014) guide the ship into a new night. They overexpress, in laforin-deficient mice, a form of laforin mutated to lack phosphatase activity, and show that this rescues murine Lafora disease. The inescapable conclusion is that the phosphatase function of laforin is dispensable, and that it is some other function of the laforin-malin complex that is relevant to the disease. The function that Gayarre et al. (2014) highlight, namely autophagy, has been of late a frequent stop in the Lafora voyage, and indeed in the exploration of many other neurodegenerative diseases. Autophagy is disturbed in Lafora disease (Criado et al., 2012), and it has been suggested that defective autophagy impairs the ability of cells to rid themselves of abnormal aggregates, such as malformed glycogen. Gayarre et al. (2014) advance the tantalizing idea that glycogen, in common with proteins, can sometimes be naturally misshapen. This would lead it to precipitate and aggregate, and indeed to accumulate were it not for mechanisms involving laforin and malin that act to clear such deposits. Before accepting autophagy as a port of call of the Lafora saga, one must however keep an open mind. Is it possible that laforin’s sole enzymatic activity is unnecessary? The vicissitudes of the Lafora epic will certainly continue to lead us to exciting lands of milk and honey most relevant to the understanding of neuronal function. But what of the patients who suffer the intractable and continuous seizures, hallucinations and dementia of Lafora disease? The polyglucosans that cause havoc in Lafora disease, irrespective of their shape or origins, are in the end nothing more than chains of glucose. One and only one enzyme, glycogen synthase, manufactures chains of glucose, and recent studies have shown that downregulation of glycogen synthesis prevents Lafora disease in mice (Pederson et al., 2014). While the Lafora pathogenesis ship feels its way through the unknown, a shortcut to safe harbour, namely glycogen synthesis downregulation, may well be open for patients with the disease. Gonzalo Lafora would have appreciated the progress made by the explorers so far.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.